Company intelligence / Profile preview

101 Therapeutics

Ownership: Private
Development stage: Phase 3

Overview

101 Therapeutics has developed a novel COVID-19 treatment that has shown exceptional efficacy against the virus and its variants. The treatment binds to immune cells called macrophages, signaling them to undergo apoptosis, which helps remove infected cells from the body and stops dangerous immune overreactions (cytokine storms). The company is currently in Phase 2 clinical trials as of April 2025[2][3].

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecule drugsTargeted glucocorticoids
Industry: Biotech

Drug pipeline

1 asset

101-PGC-005

Partnerships

Awz (Canadian-Israeli venture capital firm)

Beyond the preview

Go deeper on 101 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 101 Therapeutics.

Explore the full profile